← LIGAND PHARMACEUTICALS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $109.0m $141.1m $251.5m $120.3m $186.4m $277.1m $196.2m $131.3m $167.1m $268.1m
Cost of Revenue $5.6m $5.4m $6.3m $90.2m $96.1m $140.8m $123.1m $66.6m $111.1m $134.6m
Gross Profit (Calculated) (derived) $103.4m $135.7m $245.1m $30.1m $90.3m $136.4m $73.1m $64.7m $56.0m $133.5m
Operating expenses:
Operating Costs and Expenses $65.1m $73.0m $87.7m $126.0m $177.7m $198.2m $193.2m $121.5m $189.7m $227.1m
Operating Income (Loss) $43.9m $68.1m $163.7m $807.1m $25.8m $78.9m $3.0m $11.9m ($22.6m) $41.0m
Additional Financial Items
Amortization of Intangible Assets $10.6m $11.3m $15.8m $16.9m $23.4m $47.2m — — — —
Gain (Loss) on Investments — — — $2.9m ($16.9m) ($4.0m) $28.5m $46.4m $75.0m $18.4m
Goodwill, Impairment Loss $0 — — — — — — — — —
Income (Loss) from Continuing Operations before Income Taxes, Domestic $43.9m $68.1m $163.7m $807.1m $25.8m $78.9m $3.0m $11.9m $22.6m $126.4m
Income (Loss) from Continuing Operations, Per Basic Share ($0) $1 $7 — $0 $5 ($0) $3 ($0) $6
Income (Loss) from Continuing Operations, Per Diluted Share ($0) $1 $6 — $0 $4 ($0) $3 ($0) $6
Income (Loss) from Equity Method Investments ($23.1m) ($2.0m) $42.3m $2.9m — — — ($1.8m) ($12.8m) $0
Other Operating Income $43.9m $68.1m $163.7m $807.1m $25.8m $37.6m $3.0m $11.9m ($22.6m) $41.0m
Realized Investment Gains (Losses) $2.4m $831k $2.6m $41k — — — — — —
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $43.9m $68.1m $163.7m — $25.8m $47.3m $36.0m $63.7m $2.5m $159.0m
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax $731k $0 $0 — — — — — — —
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $43.9m $68.1m $163.7m — $25.8m $78.9m ($5.2m) $53.8m ($4.0m) $124.5m
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($2.4m) $12.6m $143.3m — $25.8m $78.9m $3.0m $11.9m $22.6m $41.0m
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $43.9m $68.1m $163.7m $807.1m $25.8m $78.9m ($28.1m) ($1.7m) $22.6m $41.0m
Net Income (Loss) Attributable to Parent ($1.6m) $12.6m $143.3m $629.3m ($3.0m) $57.1m ($33.4m) $52.2m ($4.0m) $124.5m
Net Income (Loss) Attributable to Noncontrolling Interest $0 $0 — — — — — — — —
Earnings Per Share, Basic ($0.08) $0.60 $6.77 $33.13 ($0.18) $3.44 ($1.98) $3.02 ($0.22) $6.44
Earnings Per Share, Diluted ($0.08) $0.53 $5.96 $31.85 ($0.18) $3.31 ($1.98) $2.94 ($0.22) $6.13
Weighted Average Number of Shares Outstanding, Basic 20.8m 21.0m 21.2m 19.0m 16.2m 16.6m 16.9m 17.3m 18.3m 19.3m
Weighted Average Number of Shares Outstanding, Diluted 20.8m 23.5m 24.1m 19.8m 16.2m 17.2m 16.9m 17.8m 18.3m 20.3m
Research and Development Expense $21.2m $26.9m $27.9m $55.9m $59.4m $69.0m $36.1m $24.5m $21.4m $81.2m
General and Administrative Expense $26.6m $28.7m $37.7m $41.9m $64.4m $57.5m $70.1m $52.8m $78.7m $92.4m
Other Nonoperating Income (Expense) $2.7m $5.2m ($6.3m) ($6.0m) ($108k) ($8.9m) $4.2m ($2.0m) ($54.9m) ($89k)
Interest Expense (non-operating) — — — — — — — — $3.0m $4.7m
Current Income Tax Expense (Benefit) $33k $372k $266k $92.5m $11.5m ($1.2m) $10.7m ($188k) $22.4m $12.6m
Interest Expense $12.8m $13.5m $48.3m $35.7m $27.4m $19.6m $1.8m $656k $3.0m $4.7m
Operating Lease, Expense — — — $2.1m $2.1m $2.6m $700k $1.4m $1.3m $900k
Income Tax Expense (Benefit) $10.3m $44.7m $30.0m $167.3m ($7.6m) ($9.8m) $41.2m $9.8m $6.5m $34.5m
Interest Income (Expense), Net ($12.2m) ($11.4m) — — — — — — — —
Other Operating Income (Expense), Net $43.9m $68.1m $163.7m $807.1m $25.8m $78.9m $0 $0 $22.6m $41.0m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.